| Phase 16 trials |
|
Phase 1
|
NCT07193147 |
Oct 2025 → Jul 2026 overdue |
diabetes mellitus |
Gan & Lee Pharmaceuticals. |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07146347 |
Aug 2025 → Apr 2026 overdue |
type 2 diabetes mellitus |
Gan and Lee Pharmaceuticals, USA |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06547502 |
Jul → Aug 2024 |
diabetes mellitus |
Gan and Lee Pharmaceuticals, USA |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06548906 |
May → Aug 2024 overdue |
— |
Gan and Lee Pharmaceuticals, USA |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06553248 |
Mar → Nov 2023 |
type 2 diabetes mellitus |
Gan and Lee Pharmaceuticals, USA |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06548815 |
Aug 2022 → Mar 2023 |
diabetes mellitus |
Gan and Lee Pharmaceuticals, USA |
Completed
|
No outcome recorded
|
| Phase 21 trial |
|
Phase 2
|
NCT06202079 |
Aug 2023 → Jul 2024 |
type 2 diabetes mellitus |
Gan and Lee Pharmaceuticals, USA |
Completed
|
No outcome recorded
|
| Phase 34 trials |
|
Phase 3
|
NCT07165223 |
Oct 2025 → Nov 2026 expected |
diabetes mellitus |
Gan & Lee Pharmaceuticals. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06767761 |
Feb 2025 → Mar 2026 overdue |
type 2 diabetes mellitus |
Gan & Lee Pharmaceuticals. |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06767735 |
Feb 2025 → Aug 2026 overdue |
diabetes mellitus |
Gan & Lee Pharmaceuticals. |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06767748 |
Feb 2025 → Feb 2026 overdue |
type 2 diabetes mellitus |
Gan & Lee Pharmaceuticals. |
Active not recruiting
|
No outcome recorded
|